大麻素受体在肝纤维化及肝硬化中的作用及研究进展  

Research progress on role of cannabinoid receptors in hepatic fibrosis and liver cirrhosis

作　　者：张自力[1,2] 张衍[1,2] 张涉[1,2] 段旭酉 郭瑶[1,2] 倪雯霞[1,2] 王妤清[1,2] 郑仕中[1,2,3] 

机构地区：[1]南京中医药大学药学院,江苏南京210023 [2]南京中医药大学中药学一级学科,江苏南京210023 [3]江苏省中药药效与安全性评价重点实验室,江苏南京210023

出　　处：《中国药理学通报》2014年第3期10-13,共4页Chinese Pharmacological Bulletin

基　　金：国家自然科学基金资助项目(No 81270514,30873424);“十一五”科技支撑计划(No 2008BAI51B02);教育部博士点基金资助项目(No 20103237110010);江苏省自然科学基金资助项目(No BK2008456);江苏省六大人才高峰资助项目(No 2009-B-010);江苏高校优势学科建设工程资助项目(No ysxk-2010);江苏省针灸学重点实验室开放课题(No KJA200801);南京中医药大学中药学一级学科开放课题资助(No 2011ZYX4-008)

摘　　要：肝纤维化的发生与发展是一个复杂的病理和细胞生化过程,受到多种细胞因子及细胞内多种信号转导通路网络的调控。在这个复杂的调控网络中涉及到很多作用靶标,但很多靶点在肝纤维化中的作用尚没有完全定论。发生肝纤维化后,如无有效的治疗措施,最终将恶化为肝硬化。肝硬化患者的肝脏结构发生改变,导致肝脏解毒功能下降,从而使循环血液中内毒素增加,导致肝硬化失代偿期出现门脉高压、内毒血症、高动力循环综合征、肝性脑病等并发症。近年来研究发现大麻素受体参与急、慢性肝病及其并发症的改善与恢复过程,被认为是抗肝纤维化的潜在治疗靶点。该文从大麻素系统概述、大麻素受体与肝纤维化、大麻素受体防治肝纤维化的信号通路、大麻素及其受体在肝硬化并发症中的作用等方面综述了大麻素受体在肝纤维化及肝硬化中的作用及研究进展。The progress of hepatic fibrogenesis, a complicated pathological and cellular bioehemieul process, is regulated by a multitude of eytokines and a variety of signaling pathway net- works in cells. There are enormous targets involved in this con- voluted regulation network, and many of their effects on fibrosis have not reached any conclusion yet. Recent research suggests that eannabinoid receptors participate in the amelioration and re- covery of both acute and clinical liver diseases, as well as their complications, for which they are credited with a potential target for anti-fibrotic treatments. We herein summarize the effects of eannabinoid receptors on preventing and treating hepatic fibrosis and the progress of recent relevant studies, from aspects inclu- ding the summat7 of eannabinoid receptors system, relationship between eannabinoid receptors and fibrosis, and the effects of eannabinoid receptors on preventing and treating hepatic fibrosis.

关 键 词：大麻素受体 肝纤维化 作用机制 信号通路 细胞外基质 肝星状细胞 

分 类 号：R05[医药卫生] R282